Increased blood plasma concentrations of TGF-β isoforms after treatment with intravenous immunoglobulins (IVIG) in patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 152, Issue 1-2, 2004, Pages 191-194

  Reinhold, Dirk ^a   Perlov, Evgeniy ^a   Schrecke, Kirstin ^a   Kekow, Jörn ^a   Brune, Thomas ^a   Sailer, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Intravenous immunoglobulins; Multiple sclerosis; TGF isoforms

Indexed keywords

IMMUNOGLOBULIN; INT 10; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MULTIPLE SCLEROSIS; PROTEIN ISOFORMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 3042658620     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.03.018     Document Type: Article

References (20)

1. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., Elizur A., Goldhammer Y., Sarova-Pinhas I. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 50:1998;398-402
2. Achiron A., Barak Y., Sarova-Pinhas I. Use of intravenous immunoglobulin in multiple sclerosis. BioDrugs. 9:1998;465-475
3. Danielpour D. Imroved sandwich enzyme-linked immunosorbent assays for transforming growth factor-β J. Immunol. Methods. 158:1993;17-25
4. Dwyer J.M. Manipulating the immune system with immune globulin. N. Engl. J. Med. 326:1992;107-116
5. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 349:1997;589-593
6. Jenson H.B., Pollock B.H. Meta-analyses of the effectiveness of intravenous immune globulins for prevention and treatment of neonatal sepsis. Paediatrics. 99:1997;E2
7. Kekow J., Reinhold D., Pap T., Ansorge S. Intravenous immunoglobulins and transforming growth factor β Lancet. 351:1998;184-185
8. Lewanska M., Siger-Zajdel M., Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur. J. Neurol. 9:2002;565-572
9. Pap T., Reinhold D., Kekow J. Effects of Intravenous Immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. Scand. J. Rheumatol. 27:1998;157-159
10. Pashov A., Bellon B., Kaveri S.V., Kazatchkine M.D. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Mult. Scler. 3:1997;153-156
11. Pashov A., Dubey C., Kaveri S.V., Lectard B., Huang Y.M., Kazatchkine M.D., Bellon B. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur. J. Immunol. 28:1998;1823-1831
12. Piccirillo C.A., Prud'homme G.J. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum. Gene Ther. 10:1999;1915-1922
13. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146:1991;3012-3017
14. Racke M.K., Sriram S., Carlino J., Cannella B., Raine C.S., McFarlin D.E. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J. Neuroimmunol. 46:1993;175-183
15. Reinhold D., Bank U., Bühling F., Junker U., Kekow J., Schleicher E., Ansorge S. A detailed protocol for the measurement of TGF-β in human blood samples. J. Immunol. Methods. 209:1997;203-206
16. Schiff R.I. Intravenous gammaglobulin: Pharmacology, clinical uses and mechanisms of action. Pediatr. Allergy Immunol. 5:1994;63-87
17. Schiff R.l. Intravenous gammaglobulin, 2: Pharmacology, clinical uses and mechanisms of action. Pediatr. Allergy Immunol. 5:1994;127-156
18. Sorensen P.S., Wanscher B., Jensen C.V., Schreiber K., Blinkenberg M., Ravnborg M., Kirsmeier H., Larsen V.A., Lee M.L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 50:1998;1273-1281
19. Sorensen P.S., Fazekas F., Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. J. Neurol. 9:2002;557-563
20. Szymkowiak C., Mons I., Gross W.L., Kekow J. Determination of transforming growth factor β2 in human blood samples by ELISA. J. Immunol. Methods. 184:1995;263-271